December 21, 2017 / 5:35 AM / a year ago

BRIEF-Shanghai Fosun Pharmaceutical Group unit gets approval for HLX10 clinical trail

Dec 21 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd :

* Says its Taiwan-based controlling unit gets approval from Ministry of Health and Welfare to launch clinical trail of HLX10(Recombinant Humanized Anti-PD-1 Monoclonal Antibody), which is used for treatment of solid tumor

Source text in Chinese: goo.gl/pmuXJV

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below